A major licensing agreement in the radiopharmaceutical field has drawn attention to a novel prostate cancer therapy currently in early clinical development. The therapy, known as OncoACP3, is a small-molecule ligand that targets acid phosphatase 3 (ACP3), an enzyme highly expressed in prostate cancer cells. Its dual role—as both a diagnostic imaging agent and a therapeutic—positions it at the forefront of the next wave of precision oncology tools.

Preliminary data from a phase 1 trial evaluating OncoACP3 as a PET imaging agent have shown selective uptake in prostate tumors and sustained retention over time, with minimal accumulation in healthy tissues. Encouraged by these early findings, the developers are preparing to initiate a clinical trial to investigate the same molecule as a targeted radiotherapeutic.

What makes OncoACP3 especially notable is its compatibility with alpha-emitting radioisotopes such as actinium-225. Alpha particles have a much shorter range than beta particles used in existing radiotherapies, but they deliver far more potent, localized energy—potentially resulting in greater tumor cell kill with reduced damage to surrounding healthy tissue.

The licensing agreement for OncoACP3 includes a $350 million upfront payment and could reach over $1 billion with future milestone payments, along with royalties on potential sales. The move reflects growing momentum in the radiopharmaceutical sector, which is projected to grow from $9.1 billion in 2023 to $26.5 billion by 2031, driven by rising interest in targeted therapies for hard-to-treat cancers.

This development underscores the increasing strategic focus on prostate cancer, where demand remains high for better diagnostic tools and more effective, less toxic treatments. With its novel mechanism and encouraging early data, OncoACP3 could become a key player in the next generation of cancer-targeting radiopharmaceuticals.

Source.